These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 8054280)

  • 1. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.
    Vesalainen S; Nordling S; Lipponen P; Talja M; Syrjänen K
    Br J Cancer; 1994 Aug; 70(2):309-14. PubMed ID: 8054280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinoma.
    Eskelinen M; Lipponen P; Majapuro R; Syrjänen K; Nordling S
    Eur Urol; 1991; 20(1):62-6. PubMed ID: 1743234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis.
    Bratt O; Anderson H; Bak-Jensen E; Baldetorp B; Lundgren R
    Urology; 1996 Feb; 47(2):218-24. PubMed ID: 8607238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy.
    Visakorpi T; Kallioniemi OP; Paronen IY; Isola JJ; Heikkinen AI; Koivula TA
    Br J Cancer; 1991 Sep; 64(3):578-82. PubMed ID: 1911201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-phase fraction related to prognosis in localised prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1.
    Aström L; Weimarck A; Aldenborg F; Delle U; Hanson C; Verbiene I; Danielsson A; Hammarsten J; Köpf I
    Int J Cancer; 1998 Dec; 79(6):553-9. PubMed ID: 9842961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
    Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
    Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors that influence the measurement of prostate cancer DNA ploidy and proliferation in paraffin embedded tissue evaluated by flow cytometry.
    So MJ; Cheville JC; Katzmann JA; Riehle DL; Lohse CM; Pankratz VS; Sebo TJ
    Mod Pathol; 2001 Sep; 14(9):906-12. PubMed ID: 11557788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma.
    Victorzon M; Roberts PJ; Haglund C; von Boguslawsky K; Nordling S
    Oncology; 1996; 53(3):182-91. PubMed ID: 8643219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does DNA flow cytometry give useful prognostic information in renal parenchymal adenocarcinoma?
    Masters JR; Camplejohn RS; Parkinson MC; Woodhouse CR; O'Reilly SM
    Br J Urol; 1992 Oct; 70(4):364-9. PubMed ID: 1450842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of DNA ploidy and nuclear morphometry in metastatic prostate cancer].
    Martínez Jabaloyas JM; Jiménez Sánchez A; Ruiz Cerdá JL; Sanz Chinesta S; Sempere A; Jiménez Cruz JF
    Actas Urol Esp; 2004 Apr; 28(4):298-307. PubMed ID: 15248401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
    Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
    Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of prognosis in breast cancer--the relationship between binding of the lectin HPA and histological grade, SPF, and ploidy.
    Brooks SA; Leathem AJ; Camplejohn RS; Gregory W
    Breast Cancer Res Treat; 1993; 25(3):247-56. PubMed ID: 8369526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric DNA analysis of stage D2 prostatic carcinoma.
    Yokogi H; Mizutani M; Ishibe T
    Urol Int; 1991; 47(2):57-9. PubMed ID: 1792707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer.
    Stanton PD; Cooke TG; Oakes SJ; Winstanley J; Holt S; George WD; Murray GD
    Br J Cancer; 1992 Nov; 66(5):925-9. PubMed ID: 1419638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of DNA ploidy in prostatic cancer].
    Martínez Jabaloyas JM; Ruiz Cerdá JL; Sanz Chinesta S; Jiménez A; Hernández M; Jiménez Cruz JF
    Actas Urol Esp; 2001 Apr; 25(4):283-90. PubMed ID: 11455830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications.
    Tinari N; Natoli C; Angelucci D; Tenaglia R; Fiorentino B; Di Stefano P; Amatetti C; Zezza A; Nicolai M; Iacobelli S
    Cancer; 1993 Feb; 71(4):1289-96. PubMed ID: 8435806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical parameters as prognostic factors in prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Syrjänen K
    Acta Oncol; 1995; 34(1):53-9. PubMed ID: 7865237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.
    Pinto AE; André S; Soares J
    J Clin Pathol; 1999 Aug; 52(8):604-11. PubMed ID: 10645231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour.
    Lipponen P; Vesalainen S; Kasurinen J; Ala-Opas M; Syrjänen K
    Anticancer Res; 1996; 16(4A):2095-100. PubMed ID: 8712749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology.
    Vesalainen S; Lipponen P; Nordling S; Talja M; Syrjänen K
    Anticancer Res; 1995; 15(2):569-73. PubMed ID: 7763039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.